Joseph Tubbs
Family · Batesville, MSNPI 1659769065
Payments from drug & device makers
Across 122 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- Novo Nordisk$367
- AstraZeneca$218
- Lilly USA, LLC$202
- Abbott$154
- Boehringer Ingelheim$135
- plus $490 from 12 others
What the payments were for
- Food & beverage$2,070100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $504 |
| Novo Nordisk | 20 | $367 |
| AstraZeneca | 11 | $218 |
| Lilly USA, LLC | 13 | $202 |
| Abbott | 7 | $154 |
| Boehringer Ingelheim | 9 | $135 |
| Xeris Pharmaceuticals, Inc. | 4 | $95 |
| Pfizer | 5 | $89 |
| GSK | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Bayer | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Shield Therapeutics Inc | 2 | $32 |
| Mylan Specialty L.p. | 1 | $31 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
How this compares
$2,070 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $204,394 |
| OzempicSemaglutide | 143 | $164,545 |
| EliquisApixaban | 78 | $65,769 |
| FarxigaDapagliflozin Propanediol | 63 | $63,030 |
| LinzessLinaclotide | 40 | $39,062 |
| MounjaroTirzepatide | 22 | $35,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $33,500 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $30,288 |
| RybelsusSemaglutide | 12 | $29,767 |
| EntrestoSacubitril/Valsartan | 18 | $26,660 |
| XareltoRivaroxaban | 15 | $22,747 |
| TradjentaLinagliptin | 17 | $19,888 |
| TrulicityDulaglutide | 11 | $16,372 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $12,010 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 225 | $11,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $135 | $244,965215 claims |
| Novo NordiskOzempic, Rybelsus | $367 | $194,313155 claims |
| AstraZenecaFarxiga, Symbicort | $218 | $74,10485 claims |
| PfizerEliquis | $89 | $65,76978 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $202 | $53,36545 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $55 | $44,69055 claims |
| AbbVieLinzess | $504 | $39,06240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.
Other family in Batesville
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.